Aevisbio
IMiD-based targeted protein degradation for neurological diseases
- Headquarters
- Daejeon
- Employees
- 1–10
- Business Model
- B2B
- Website
- aevisbio.com
About
AevisBio is a clinical-stage biopharmaceutical company focused on developing next-generation immunomodulatory imide drug (IMiD)-based therapeutics for neurological and neuroinflammatory diseases. The company leverages targeted protein degradation technology derived from IMiD-cereblon interactions to develop novel small-molecule treatments for conditions including Alzheimer's disease, ischemic stroke, and other neurodegenerative disorders. AevisBio has a dual presence with operations in Daejeon, Republic of Korea and Gaithersburg, Maryland, USA. Its lead pipeline candidates AEV-103 and AEV-003 are advancing through IND-enabling studies in collaboration with the U.S. National Institutes of Health (NIH).
Summary
Aevisbio is a Biotech company based in Daejeon, South Korea.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/aevisbio"><img src="https://indexed.vc/api/badge/company/aevisbio" alt="Aevisbio on Indexed.vc" width="260" height="76" /></a>